compani
in-lin sale mix qualiti
report revenu non-gaap ep y/i y/i
came vs our/street forecast top-line perform
mix ciali beat vs bofaml off-set weak
humalog vs sever key diabet product collect
under-perform forecast jardianc basaglar tradjenta rais
sale ep mid-point respect mainli due bp
lower tax rate base result oper trend modestli increas
out-year sale ep respect mainli due higher trulic
see ahead investor day adjust sale ep
versu bloomberg con respect revis
po vs prior reiter neutral believ share
unlik re-rat premium multipl limit clinic catalyst
management tone bullish rewind increas forecast
follow yesterday posit headlin result trulic rewind studi cv
outcom trial type diabet management field numer question mean
preced set result report yesterday management offer limit detail
rewind detail result expect ada american diabet associ june
management point potenti cv cardiovascular label claim updat
would specul breadth indic given posit updat
forecast trulic modestli expand us share market
forecast convers lli combin
diabet price broadli drag
fell short forecast sever diabet product humalog
jardianc tradjenta basaglar management affirm humalog
weak due time rebat sale adjust wherea ytd basi us
price eros mid-singl digit better indic price trend basaglar neg
impact increas medicar part access come higher rebat given
quarterli variabl product make modest out-yr revenu
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
timestamp novemb estcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani novemb
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough target
new po vs prior reflect estim chang note front page
well updat discount rate wacc vs prior line
discount rate assumpt us pharma peer
compani novemb
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum wacc
termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-year-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani novemb
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani novemb
